Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $283M | $138M | $287M | $135M | 49.4% | 20.4% | 4893.1% |
| 2024 | $235M | $32M | $6M | $44M | 1.5% | 34.0% | -107.4% |
| 2023 | $176M | $-63M | $-78M | $-34M | -20.6% | 31.0% | -27.9% |
| 2022 | $134M | $-104M | $-108M | $-80M | -26.7% | - | - |
| 2021 |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 283.06 |
| Operating Revenue | 283.06 |
| Cost Of Revenue | 32.66 |
| Gross Profit | 250.39 |
| Operating Expense | 143.83 |
| Research And Development | 32.51 |
| Selling General And Administration | 101.79 |
| Total Expenses | 176.49 |
| Operating Income | 106.56 |
| Total Operating Income As Reported | 104.91 |
| EBITDA | 137.94 |
| Normalized EBITDA | 139.58 |
| EBIT | 118.49 |
| Interest Income | 13.57 |
| Interest Expense | 4.33 |
| Net Interest Income | 9.24 |
| Other Income Expense | -1.65 |
| Interest Income Non Operating | 13.57 |
| Interest Expense Non Operating | 4.33 |
| Net Non Operating Interest Income Expense | 9.24 |
| Pretax Income | 114.16 |
| Tax Provision | -173.04 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | -0.35 |
| Net Income Continuous Operations | 287.20 |
| Net Income From Continuing And Discontinued Operation | 287.20 |
| Net Income From Continuing Operation Net Minority Interest | 287.20 |
| Net Income | 287.20 |
| Net Income Common Stockholders | 287.20 |
| Net Income Including Noncontrolling Interests | 287.20 |
| Normalized Income | 288.50 |
| Diluted NI Availto Com Stockholders | 287.20 |
| Basic Average Shares | 134.37 |
| Diluted Average Shares | 138.70 |
| Reconciled Depreciation | 19.45 |
| Reconciled Cost Of Revenue | 32.66 |
| Total Unusual Items | -1.65 |
| Total Unusual Items Excluding Goodwill | -1.65 |
| Special Income Charges | -1.65 |
| Restructuring And Mergern Acquisition | 1.65 |
| Depreciation Amortization Depletion Income Statement | - |
| Depreciation And Amortization In Income Statement | - |
| General And Administrative Expense | 98.59 |
| Other Gand A | 41.30 |
| Salaries And Wages | 57.29 |
| Other Operating Expenses | 9.53 |
| Selling And Marketing Expense | 3.21 |
| Amortization | - |
| Amortization Of Intangibles Income Statement | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Aurinia Pharmaceuticals Inc.this co. | AUPH | $2.1B | 7.33 | 3.62 | 49.4% | 15.22 |
| Mineralys Therapeutics, Inc. | MLYS | $2.2B | -14.28 | 3.41 | -23.9% | - |
| Enliven Therapeutics, Inc. | ELVN | $2.2B | -20.85 | 4.70 | -22.6% | -17.28 |
| BioCryst Pharmaceuticals, Inc. | BCRX | $2.2B | 8.16 | -18.07 | -221.4% | 7.20 |
| Kodiak Sciences Inc. | KOD |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $2.1B |
| - |
| 13.58 |
| -146.1% |
| - |
| Clover Health Investments, Corp. | CLOV | $2.1B | -24.56 | 6.81 | -27.7% | - |
| NovoCure Limited | NVCR | $2.1B | - | 6.12 | -40.0% | - |
| Intellia Therapeutics, Inc. | NTLA | $2.1B | - | 3.07 | -61.5% | - |
| Recursion Pharmaceuticals, Inc. | RXRX | $2.0B | -3.13 | 1.78 | -57.0% | -2.42 |
| Peer Median | - | -14.28 | 4.06 | -48.5% | -2.42 | |